Search Beyond News…

Cognizant and Benchling partner to streamline Kyowa Kirin's R&D with AI-driven data management and automation

Executive summary: Cognizant and Benchling were selected as partners to support Kyowa Kirin's R&D through integrated data management, advanced automation, and AI-driven workflows. The alliance aims to increase R&D efficiency, potentially shortening drug development timelines and reducing costs for Kyowa Kirin.

Who is involved: Cognizant (NASDAQ: CTSH), Benchling (AI R&D platform provider), and Kyowa Kirin (Japanese pharmaceutical company).

Likely next: Implementation of Benchling's platform across Kyowa Kirin's research sites, with measurable outcomes expected in subsequent quarters.

On August 16, 2026, Cognizant announced it will support the introduction and implementation of Benchling's AI platform to accelerate Kyowa Kirin's research and development processes. The collaboration aims to integrate data management, automate workflows, and apply AI to improve efficiency in Kyowa Kirin's R&D lifecycle. Both Cognizant and Benchling bring complementary expertise in enterprise IT solutions and scientific R&D software, while Kyowa Kirin seeks to reduce time-to-market for its therapeutics. The partnership reflects a broader trend of pharmaceutical companies leveraging external AI and automation specialists to enhance productivity.

Timeline

Sources

Related cases

Browse the full archive →